Abstract
The significance of the study is due to the problem of the increase in patients with secondary forms of leukopoiesis-depressive diseases. The development of leukopoiesis-stimulating drugs is necessary. These drugs are used in the treatment of cancer patients to prevent the development of febrile neutropenia, to stimulate the immune system in the postoperative period, to restore immune reactivity in environmentally caused secondary immunodeficiency syndrome. The rate of increase in patients with the secondary form of leukopoiesis-depressive syndrome is due to the increased use of cytostatic drugs. Preclinical work was carried out to study new synthetic compounds BIV-241 (dimethyl ((4-methoxyphenyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methyl)phosphonate), BIV-242 (dimethyl ((3-methoxyphenyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methyl)phosphonate), BIV-243 (dimethyl ((2-fluorophenyl)(4-(pyrimidin-2-yl)piperazin-1-yl)methyl)phosphonate) for leukopoiesis-stimulating activity. The studies were conducted on a cyclophosphamide-induced model of pancytopenia on outbred white rats. Compounds BIV-241 and BIV-242 did not show the desired activity. Compound BIV-243 is of interest for further development, as it had moderate leukopoiesis-, erythrocytopoiesis- and thrombocytopoiesis-stimulating activity.